At the end of the first year of the COVID-19 pandemic, more than 78 million known survivors were recorded. The long-term pulmonary sequelae of COVID-19 remain unknown.
We performed a retrospective analysis of a post-COVID follow-up service to estimate the burden of persistent pulmonary morbidity in hospitalised COVID survivors.
A total of 221 patients were followed-up 44 intensive care unit (ICU) and 177 ward patients. Further investigations were planned as per British Thoracic Society Guidelines For all ICU patients (n=44) and for 38 of 177 (21%) ward-based patients who had persistent symptoms and/or persistent radiographic changes on CXR at their initial 8-week follow-up visit. In the ward-based cohort, statistically significant associations with persistent symptoms were being an ex- or current smoker, having pre-existing diabetes, and having a longer length of stay. In patients requiring further investigations, pulmonary function tests (PFTs; n=67) at an average of 15weeks post-discharge showed abnorm.
To assess the clinical and cost-effectiveness of therapeutic drug monitoring (TDM) based on serum adalimumab levels compared to standard of care in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
This was a non-inferiority, multicentric, non-randomized, pragmatic trial including adult patients diagnosed with moderate-to-severe, clinically stable rheumatic diseases treated with adalimumab. Consecutive patients were assigned 12 to the control (CG) or the intervention group (IG), based on the site of inclusion, and followed up for 18months. Adalimumab serum levels were measured at each study visit and released to the IG only to modify dosing strategy. Data on disease activity, healthcare resource utilization and health-related quality of life (HRQoL) measured through the EQ-5D-5L were collected. Number of persistent and overall flares, time to first flare, days experiencing high disease activity, total direct costs, quality-adjusted life years (QALYs) and incremental cost-agement.
Of the 169 recruited patients, 150 were included in the analysis (52 and 98 patients in the CG and IG, respectively). The primary endpoint was not met as persistent flares were not significantly lower in the IG, although mean (SD) number of flares was numerically lower in the IG (0.67 [0.70] versus 0.90 [0.82], P = 0.073), respectively. Based on EQ-5D-5L utilities, HRQoL was significantly higher in the IG at 3 (P = 0.001) and 6 months (P = 0.035), which overall translated into 0.075 QALYs gained per patient for the IG at month 18. Overall, direct costs were significantly lower for the IG patients (€15,311.59 [4,870.04] versus €17,378.46 [6,556.51], P = 0.030), resulting in the intervention being dominant, leading to increased QALY at a lower overall cost CONCLUSION Adalimumab dose tapering based on TDM for rheumatic patients led to an increased quality of life and QALY gain and entailed lower costs, being a more cost-effective alternative than clinically guided management.Pharmaceuticals are present in natural waters, thus contributing to the general exposure of aquatic organisms, but few data are available on the accumulation of these substances in marine organisms. The present study evaluated the in vivo bioconcentration of an antidepressant-venlafaxine (VLF)-in marine mussels (Mytilus galloprovincialis) during 7 days of exposure at nominal 10 μg/L concentration, followed by a 7-day depuration period. The bioconcentration factor (BCF) was 265 mL/g dry weight (dw). VLF accumulation reached an average tissue concentration of 2146 ± 156 ng/g dw within 7 days, showing a first-order kinetics process. N-desmethylvenlafaxine (N-VLF) and O-desmethylvenlafaxine (O-VLF) metabolites were quantified in mussel tissues, whereas N,N-didesmethylvenlafaxine (NN-VLF) was only recorded as being detected. These three metabolites were also quantified in water, indicating an active metabolism and VLF excretion in Mediterranean mussels. Complementary experiments conducted at nominal concentrations of 1, 10, and 100 μg/L for 7 days confirmed the VLF bioconcentration and metabolism and allowed us to quantify a supplementary metabolite, i.e., N,O-didesmethylvenlafaxine (NO-VLF), in mussel tissues. These results encourage further research on a more complete characterization of metabolism and on any disturbances linked to bioconcentration of VLF on bivalves.This literature review outlines the most important-agricultural and non-agricultural-types of sewage sludge management. The potential of waste sludge protein hydrolysates obtained by chemical sludge conditioning was reported. The discussed areas include acidic and alkaline hydrolysis, lime conditioning, polyelectrolyte dewatering and other supporting techniques such as ultrasounds, microwave or thermal methods. The legislative aspects related to the indication of the development method and admission to various applications based on specified criteria were discussed. Particular attention was devoted to the legally regulated content of toxic elements cadmium, lead, nickel, mercury, chromium and microelements that may be toxic copper and zinc. Various methods of extracting valuable proteins from sewage sludge have been proposed chemical, physical and enzymatic. While developing the process concept, you need to consider extraction efficiency (time, temperature, humidity, pH), drainage efficiency of post-extraction residues and directions of their management. The final process optimization is crucial. Despite the development of assumptions for various technologies, excess sewage sludge remains a big problem for sewage treatment plants. The high costs of enzymatic hydrolysis, thermal hydrolysis and ultrasonic methods and the need for a neutralizing agent in acid solubilization limit the rapid implementation of these processes in industrial practice.Cement industry is one of the main contributors to greenhouse gas (GHG) emissions, specifically carbon dioxide (CO2). This paper presents the cement production and the CO2 emissions from the cement industry in Nepal. We compute emissions for the process-related, combustion-related (fuel use), and electricity-related activities during the cement production. We used eight emission factors (EFs) for the process-related, two EFs for the combustion or fuel-related, and two for the electricity-related activities using the previous researches. We computed the emissions as a product of the activities and the EFs. The estimated CO2 emission in 2019 from the cement production is 3.45 ± 0.50 million metric tons (mMt) for Nepal. Cyclopamine mouse In 2019, the emissions are 1.87 ± 0.16 mMt from the process-related, 1.52 ± 0.34 mMt from the combustion-related, and 0.062 ± 0.004 mMt from the electricity use activities during the cement production in Nepal. Cumulative CO2 emission was 22.73 ± 3.82 mMt from 1987 to 2019. Per capita CO2 emission is 0.Cyclopamine mouse
Top comments (0)